The estimated Net Worth of Julie Burek is at least $365 ezer dollars as of 21 March 2022. Ms Burek owns over 2,649 units of Voyager Therapeutics Inc stock worth over $329,436 and over the last 3 years she sold VYGR stock worth over $35,459.
Ms has made over 4 trades of the Voyager Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 2,649 units of VYGR stock worth $21,960 on 21 March 2022.
The largest trade she's ever made was selling 3,328 units of Voyager Therapeutics Inc stock on 3 January 2022 worth over $9,485. On average, Ms trades about 1,188 units every 13 days since 2021. As of 21 March 2022 she still owns at least 52,458 units of Voyager Therapeutics Inc stock.
You can see the complete history of Ms Burek stock trades at the bottom of the page.
Julie Burek is the VP of Fin. at Voyager Therapeutics Inc.
Ms Burek is 46, she's been the VP of Fin. of Voyager Therapeutics Inc since . There are 14 older and 1 younger executives at Voyager Therapeutics Inc. The oldest executive at Voyager Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the Exec. Science Advisor & Director.
Julie's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC.,, 75 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 és Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include: